Abstract
The methylphenidate transdermal system (MTS) is the only nonoral medication approved by the US FDA for treating the symptoms of attention-deficit/hyperactivity disorder (ADHD). MTS patches deliver methylphenidate through the skin directly into the bloodstream, largely circumventing the first-pass metabolism of the GI tract and liver that occurs with orally administered methylphenidate. Clinical studies in school-aged children have shown MTS to be well tolerated and effective in the treatment of ADHD. Adverse effects most commonly seen in clinical studies are consistent with those seen with the use of other methylphenidate products and include decreased appetite, insomnia, headache, nausea, vomiting, anorexia and weight loss. When worn for the recommended 9 h, MTS demonstrated significant reductions in the core symptoms of ADHD from 2 through 12 h post-application.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
